ライフサイエンスコーパス: small cell lung cancer

1 RAS are now routine in the management of non-small cell lung cancer.

2 ministering immunotherapy in early-stage non-small cell lung cancer.

3 ibitor used as second-line treatment for non-small cell lung cancer.

4 inhibitors remains a major challenge in non-small cell lung cancer.

5 and are associated with smoking-related non-small cell lung cancer.

6 owth factor receptor-targeted therapy in non-small cell lung cancer.

7 P) and Importin 8 (IPO8) to be stable in non-small cell lung cancer.

8 ential as a new therapeutic approach for non-small cell lung cancer.

9 chemosensitive and chemoresistant models of small cell lung cancer.

10 and peripheral blood from patients with non-small cell lung cancer.

11 terogeneity and evolution in early-stage non-small cell lung cancer.

12 -FDG PET quantification in patients with non-small cell lung cancer.

13 dvanced melanoma, renal cell cancer, and non-small cell lung cancer.

14 iotherapy treatment regimen in limited-stage small-cell lung cancer.

15 th tumour suppressive and pro-tumorigenic in small-cell lung cancer.

16 expressed in more than 80% of patients with small-cell lung cancer.

17 axel in previously treated patients with non-small-cell lung cancer.

18 ctivity, in patients with ALK-rearranged non-small-cell lung cancer.

19 ment; this report focuses on the cohort with small-cell lung cancer.

20 bination therapies) for stage IIIB or IV non-small-cell lung cancer.

21 ognostic marker for survival in resected non-small-cell lung cancer.

22 been referred for treatment of advanced non-small-cell lung cancer.

23 patients with operable locally advanced non-small-cell lung cancer.

24 pressed by many solid tumours, including non-small-cell lung cancer.

25 efit to a number of staging scenarios in non-small-cell lung cancer.

26 apy (SBRT) for patients with early-stage non-small-cell lung cancer.

27 on with chemotherapy in select patients with small-cell lung cancer.

28 arget for upregulation by mutant KRAS in non-small cell lung cancers.

29 e I/II clinical trial investigations for non-small cell lung cancers.

30 adjuvant therapy guideline for resected non-small-cell lung cancers.

31 RET rearrangements are found in 1-2% of non-small-cell lung cancers.

32 vestigating adjuvant therapy in resected non-small-cell lung cancers.

33 were eligible for inclusion, 42 (39%) in non-small-cell lung cancer, 36 (33%) in breast cancer, 25 (2

34 previously treated advanced KRAS-mutant non-small cell lung cancer, addition of selumetinib to docet

35 this study, we analysed LSD1 function in non-small cell lung cancer adenocarcinomas.

36 cancer on DCE-MRI in 65 studies and (3) non-small cell lung cancer (adenocarcinomas) from benign fun

37 Three of five patients with small-cell lung cancer, all of whom had platinum-refract

38 lected cancer patients, most especially with small cell lung cancer, although the long-term survival

39 In small-cell lung cancer, an aggressive neuroendocrine lun

40 exhibits efficacy in pancreatic cancer, non-small cell lung cancer and breast cancer.

41 oantigens were identified in early-stage non-small cell lung cancer and expressed high levels of PD-1

42 RCD1 was down-regulated in patients with non-small cell lung cancer and lung adenocarcinoma cell line

43 pact on tumorigenesis in mouse models of non-small cell lung cancer and melanoma, loss of both blocke

44 In small cell lung cancer and mesothelioma, the efficacy of

45 etables" pattern, and stronger for other non-small cell lung cancer and never smokers for the "Americ

46 Patients with inoperable stage III or IV non-small-cell lung cancer and cachexia (defined as >/=5% we

47 t, on cachexia in patients with advanced non-small-cell lung cancer and cachexia.

48 ts were enrolled, including 74 patients with small-cell lung cancer and eight with large-cell neuroen

49 , including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma.

50 n 10-50% of tumour cells in a mouse model of small-cell lung cancer and in human tumours.

51 of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerg

52 We assessed outcomes in patients with non-small-cell lung cancer and the EGFR Thr790Met mutation w

53 al immune target in melanoma, but not in non-small cell lung cancer, and implicates SPAG5 as an alter

54 urvival rates of small cell lung cancer, non-small cell lung cancer, and non-lung cancer patients all

55 b is used in advanced melanoma, advanced non-small-cell lung cancer, and in head and neck cancer.

56 umor immunity in patients with melanoma, non-small-cell lung cancer, and renal cell cancer.

57 oradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and low

58 In non-small cell lung cancer, anti-PD-1 antibodies have become

59 ibitor resistance mechanisms.EGFR-mutant non-small cell lung cancer are often resistant to EGFR tyros

60 high-grade serous ovarian, oesophageal, and small-cell lung cancer, are driven by somatic structural

61 e (ProGRP), a highly sensitive biomarker for Small Cell Lung Cancer, as a model.

62 of forty-seven patients with early-stage non-small cell lung cancer before and after three weeks of t

63 ars of age with newly diagnosed advanced non-small-cell lung cancer benefit from platinum-based combi

64 ntrolled trials of systemic therapies in non-small-cell lung cancer, breast cancer, colorectal cancer

65 apy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy sch

66 luster are significantly co-repressed in non-small cell lung cancer cell lines and primary tumors fro

67 targeting reduced mitogenic signaling in non-small cell lung cancer cell lines, suggesting that targe

68 receptor (EGFR) inhibitor, erlotinib, in Non-Small Cell Lung Cancer cell lines.

69 tro system to delineate their effects on non-small cell lung cancer cell proliferation and apoptosis.

70 ata-driven approach, utilizing 106 human non-small-cell lung cancer cell lines, was used to interroga

71 nanosomes was assessed in H1299 and A549 non-small cell lung cancer cells, normal MRC9 lung fibroblas

72 recapitulated in mutant KRAS homozygous non-small-cell lung cancer cells and in vivo, in spontaneous

73 Non-neuroendocrine Notch-active small-cell lung cancer cells are slow growing, consisten

74 Eighty-six patients with non-small cell lung cancer, colorectal liver metastases, or

75 ly or histologically confirmed limited-stage small-cell lung cancer, Eastern Cooperative Oncology Gro

76 metastatic or polymetastatic extensive stage small-cell lung cancer (ES-SCLC) to the overall survival

77 ed treatments for patients with advanced non-small-cell lung cancer, especially focusing on data from

78 ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) s

79 73 patients with advanced non-small cell lung cancer from the prospective multicenter

80 ial histologic sections from 90 archival non-small cell lung cancers from January 1, 2008, to Decembe

81 antiprogrammed cell death-1 therapy for non-small cell lung cancer, from May 2012 to September 2014.

82 as CTLA-4 and PD-1 can cure melanoma and non-small cell lung cancer in a subset of patients.

83 report here a novel orthotopic model of non-small cell lung cancer in rats, where we have studied th

84 comes of patients diagnosed with stage 1 non-small cell lung cancer in the NLST to a nationally repre

85 ertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the EGFR

86 ly identified as a prognostic marker for non-small cell lung cancer, in cerebrovascular pathogenesis

87 In murine models of small-cell and non-small cell lung cancers, including patient-derived xenog

88 t downregulation of LZTFL1 expression in non-small cell lung cancer is associated with recurrence and

89 y that resistance to targeted therapy in non-small cell lung cancer is highly dynamic, and also one w

90 Small cell lung cancer is initially highly responsive to

91 evolved resistance in an ALK rearranged non-small cell lung cancer line (H3122) to a panel of 4 ALK

92 limiting its utility in the treatment of non-small cell lung cancer metastases in the brain.

93 alignant neoplasms, including metastatic non-small cell lung cancer (mNSCLC).

94 EGFR tyrosine kinase inhibitor-resistant non-small-cell lung cancer models.

95 into small cell lung cancer (n = 57) and non-small cell lung cancer (n = 33).

96 the most common malignancy distributed into small cell lung cancer (n = 57) and non-small cell lung

97 based detection of early- and late-stage non-small-cell lung cancer (n = 518 late-stage validation co

98 sustained since the 1-year survival rates of small cell lung cancer, non-small cell lung cancer, and

99 S, respectively) in early-stage I and II non-small cell lung cancer (NSCLC) after resection.

100 ted with these workflows, we analyzed 32 non-small cell lung cancer (NSCLC) and 22 breast cancer pati

101 qCC) are the two predominant subtypes of non-small cell lung cancer (NSCLC) and are distinct in their

102 Dose-dependent synergy was observed in Non-Small Cell Lung Cancer (NSCLC) and Head and Neck Squamou

103 of the most frequently mutated genes in non-small cell lung cancer (NSCLC) and is commonly comutated

104 f Notch signaling is a common feature of non-small cell lung cancer (NSCLC) and is correlated with po

105 YEATS2 gene is highly amplified in human non-small cell lung cancer (NSCLC) and is required for cance

106 sis suppressor 1 (BRMS1) is decreased in non-small cell lung cancer (NSCLC) and other solid tumors, a

107 le inhibitor directed against HuR, using non-small cell lung cancer (NSCLC) as a model.

108 aspiration (EBUS-TBNA) in patients with non-small cell lung cancer (NSCLC) can facilitate the select

109 molecule inhibitor (HL001) that induces non-small cell lung cancer (NSCLC) cell cycle arrest and apo

110 tem cell marker Lgr6 becomes enriched in non-small cell lung cancer (NSCLC) cells during malignant pr

111 er siRNA to cytoplasm of KRAS mutant H23 Non-Small Cell Lung Cancer (NSCLC) cells for oncogene knockd

112 ion and invasion in KRAS- or EGFR-mutant non-small cell lung cancer (NSCLC) cells.

113 ic function that drives the phenotype of non-small cell lung cancer (NSCLC) cells.

114 f its protein (BRG1) occur frequently in non-small cell lung cancer (NSCLC) cells.

115 whether radiomics features measured from non-small cell lung cancer (NSCLC) change during therapy and

116 Non-small cell lung cancer (NSCLC) comprises 85-90% of lung

117 ine therapy in the treatment of advanced non-small cell lung cancer (NSCLC) harboring ALK rearrangeme

118 ion within the tumor microenvironment in non-small cell lung cancer (NSCLC) has not yet been adequate

119 Non-small cell lung cancer (NSCLC) is characterized by early

120 Non-small cell lung cancer (NSCLC) is heterogeneous in the g

121 origenicity, invasion, and metastases in non-small cell lung cancer (NSCLC) lines.

122 ISPR, shRNA, and expression screens in a non-small cell lung cancer (NSCLC) model.

123 0.001), but the worst OS was observed in non-small cell lung cancer (NSCLC) patients (HR = 3.11, 95%C

124 udinal blood samples from advanced stage non-small cell lung cancer (NSCLC) patients (n = 29) receivi

125 titative whole-body (18)F-FDG metrics in non-small cell lung cancer (NSCLC) patients as a function of

126 onse are unpredictable in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with cri

127 sis to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the

128 Non-small cell lung cancer (NSCLC) patients with tumors harb

129 time, to our knowledge, in stage III-IV non-small cell lung cancer (NSCLC) patients.

130 uring DCs with pooled sera from multiple non-small cell lung cancer (NSCLC) patients.

131 dict poor long-term survival in resected non-small cell lung cancer (NSCLC) patients.

132 39 correlates with lower survival in 210 non-small cell lung cancer (NSCLC) patients.

133 c (18)F-FDG PET for tumor delineation in non-small cell lung cancer (NSCLC) radiation therapy plannin

134 s used on the plasma of 48 patients with non-small cell lung cancer (NSCLC) to detect EGFR mutations.

135 inical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-bas

136 me sequencing analysis of an EGFR-mutant non-small cell lung cancer (NSCLC) tumor biopsy from a patie

137 ntification of patients with early stage non-small cell lung cancer (NSCLC) with high risk of recurre

138 aging in determining the nodal status of non-small cell lung cancer (NSCLC) with the aim of elucidati

139 dely used to treat brain metastases from non-small cell lung cancer (NSCLC), although there have been

140 to be effective in a subset of melanoma, non-small cell lung cancer (NSCLC), and kidney cancers.

141 efinitive management of locally advanced non-small cell lung cancer (NSCLC), but long-term prospectiv

142 ommonly inactivated tumor suppressors in non-small cell lung cancer (NSCLC), especially in tumors har

143 the HDI-based anticancer therapeutics in non-small cell lung cancer (NSCLC), in the present study, we

144 ost common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer.

145 Among them, 20 studies of melanoma, non-small cell lung cancer (NSCLC), or renal cell carcinoma

146 To improve treatment outcomes in non-small cell lung cancer (NSCLC), preclinical models that

147 of subtype-specific prognostic genes for non-small cell lung cancer (NSCLC), we had previously propos

148 genic role in mediating tumorigenesis in non-small cell lung cancer (NSCLC).

149 ivity on clinical outcomes in RT-treated non-small cell lung cancer (NSCLC).

150 enes has revolutionized the treatment of non-small cell lung cancer (NSCLC).

151 hemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC).

152 ated by RNA sequencing for patients with non-small cell lung cancer (NSCLC).

153 th bevacizumab in patients with advanced non-small cell lung cancer (NSCLC).

154 th one common strategy remain unclear in non-small cell lung cancer (NSCLC).

155 t indices and prognosis in patients with non-small cell lung cancer (NSCLC).

156 h chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC).

157 type compounds that were active against lung small cell lung cancer (NSCLC).

158 of the most common type of lung tumors, non-small cell lung cancer (NSCLC).

159 termed GAS5-AS1 as a tumor suppressor in non-small cell lung cancer (NSCLC).

160 metformin is an effective treatment for non-small cell lung cancer (NSCLC).

161 rks a drastic change in the treatment of non-small cell lung cancer (NSCLC).

162 -oncogenic alterations commonly found in non-small cell lung cancer (NSCLC).

163 ronment and blood serum of patients with non-small cell lung cancer (NSCLC).

164 ntial treatment strategy for KRAS mutant non-small cell lung cancers (NSCLC) and colorectal carcinoma

165 ective study, 36 patients with stage III non-small cell lung cancers (NSCLC), who underwent dynamic c

166 ic Assessment (DS-GPA) for patients with non-small-cell lung cancer (NSCLC) and brain metastases.

167 abolism, thereby selectively sensitizing non-small-cell lung cancer (NSCLC) and glioblastoma (GBM) ce

168 mal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) are associated with poor

169 patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxe

170 of the patients with completely resected non-small-cell lung cancer (NSCLC) are cured.

171 r ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine

172 who previously received radiotherapy for non-small-cell lung cancer (NSCLC) before receiving pembroli

173 that CLCb is specifically upregulated in non-small-cell lung cancer (NSCLC) cells and is associated w

174 Ras-independent, but not K-Ras-dependent non-small-cell lung cancer (NSCLC) cells.

175 g cause of cancer deaths worldwide, with non-small-cell lung cancer (NSCLC) constituting more than 80

176 Non-small-cell lung cancer (NSCLC) demonstrates remarkable m

177 Purpose Multiple agents for advanced non-small-cell lung cancer (NSCLC) have been approved in the

178 Non-small-cell lung cancer (NSCLC) is globally prevalent and

179 immune checkpoint inhibitor therapy for non-small-cell lung cancer (NSCLC) is just 20%.

180 plastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known.

181 ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK tyros

182 -associated cardiac injury for stage III non-small-cell lung cancer (NSCLC) is unclear, but higher he

183 r first-line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at site

184 ession profiling of individual CTCs from non-small-cell lung cancer (NSCLC) patients with remarkable

185 Is) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients.

186 ving anti-PD-1 or anti-PD-L1 therapy for non-small-cell lung cancer (NSCLC) presented hair repigmenta

187 ed survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with c

188 nt chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest surviva

189 Here, we analyzed non-small-cell lung cancer (NSCLC) specimens and cell lines

190 inhibitors has changed the landscape of non-small-cell lung cancer (NSCLC) therapy, with 2 approvals

191 n both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) to try to improve inciden

192 its clinical-pathologic significance in non-small-cell lung cancer (NSCLC) was investigated.

193 itor approved for patients with advanced non-small-cell lung cancer (NSCLC) whose epidermal growth fa

194 patients with treatment-naive, advanced non-small-cell lung cancer (NSCLC) with a programmed cell de

195 Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heter

196 reasingly used to treat locally advanced non-small-cell lung cancer (NSCLC), IMRT and three-dimension

197 ocally advanced or incompletely resected non-small-cell lung cancer (NSCLC), it remains uncertain whe

198 shown promise in patients with advanced non-small-cell lung cancer (NSCLC), particularly with squamo

199 blockade, have improved the treatment of non-small-cell lung cancer (NSCLC), supporting the premise t

200 in patients with EGFR Thr790Met-positive non-small-cell lung cancer (NSCLC), who had progressed after

201 l component in the care of patients with non-small-cell lung cancer (NSCLC), yet cardiac injury after

202 ogenic transcription and tumor growth in non-small-cell lung cancer (NSCLC).

203 t for antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).

204 ts with advanced squamous or nonsquamous non-small-cell lung cancer (NSCLC).

205 ly treated BRAF(V600E)-mutant metastatic non-small-cell lung cancer (NSCLC).

206 local tumor control of locally advanced non-small-cell lung cancer (NSCLC).

207 with platinum resistance and survival in non-small-cell lung cancer (NSCLC).

208 metabolism and are frequently mutated in non-small-cell lung cancer (NSCLC).

209 malignant pleural mesothelioma (MPM) or non-small-cell lung cancer (NSCLC).

210 l among patients with previously treated non-small-cell lung cancer (NSCLC).

211 eviously treated, advanced or metastatic non-small-cell lung cancer (NSCLC).

212 reviously treated patients with advanced non-small-cell lung cancer (NSCLC).

213 rearrangements are oncogenic drivers of non-small-cell lung cancer (NSCLC).

214 1) is mutated in 20-30% of patients with non-small-cell lung cancer (NSCLC).

215 line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC).

216 able clinical responses in patients with non-small-cell lung cancer (NSCLC).

217 (ALK) gene associated with ALK-positive non-small-cell lung cancer (NSCLC).

218 metastases in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).

219 docetaxel in previously treated advanced non-small-cell lung cancer (NSCLC).

220 ients with ALK-rearranged (ALK-positive) non-small-cell lung cancer (NSCLC).

221 nts with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC).

222 dictive roles of TP53, KRAS, and EGFR in non-small-cell lung cancer (NSCLC).

223 t imparts a robust anti-tumor effect for non-small-cell lung cancer (NSCLC).

224 patients with advanced, platinum-treated non-small-cell lung cancer (NSCLC).

225 as been associated with worse outcome in non-small-cell lung cancer (NSCLC).

226 ptor that we have shown is important for non-small-cell lung cancer (NSCLC).

227 temic therapy for patients with stage IV non-small-cell lung cancer (NSCLC).

228 utation of LKB1, frequently occurring in non-small cell lung cancers (NSCLCs), is a predominant cauti

229 A, we find that HLA LOH occurs in 40% of non-small-cell lung cancers (NSCLCs) and is associated with

230 and it is often genetically activated in non-small-cell lung cancers (NSCLCs) by, for instance, mutat

231 We previously reported that human non-small-cell lung cancers (NSCLCs) oxidize glucose in the

232 ing pathway is frequently deregulated in non-small-cell lung cancer, often through KRAS activating mu

233 ad histologically or cytologically confirmed small-cell lung cancer or large-cell neuroendocrine tumo

234 Non-small cell lung cancer patients carrying oncogenic EGFR

235 chemotherapy combined with radiation in Non-Small Cell Lung Cancer patients for use in clinical tria

236 -smoker or former light smoker, advanced non-small cell lung cancer patients of Asian origin.

237 Three hundred forty-eight non-small cell lung cancer patients underwent diagnostic (18

238 prompt a beneficial clinical response in non-small cell lung cancer patients who harbor activating mu

239 on a later CT scan in erlotinib-treated non-small cell lung cancer patients.

240 diomic features for somatic mutations in non-small cell lung cancer patients.

241 fter 7-10 d of erlotinib treatment in 50 non-small cell lung cancer patients.

242 tribution and dosimetry of (18)F-FAZA in non-small cell lung cancer patients.

243 ical specimens obtained from EGFR-mutant non-small-cell lung cancer patients with acquired EGFR tyros

244 Non-small-cell lung cancer patients with activating epiderma

245 thod to quantify radiosensitivity in 134 non-small-cell lung cancer patients, by using K-Means cluste

246 ven pancreatic cancer, laryngeal cancer, non-small cell lung cancer, prostate cancer, melanoma, breas

247 carboplatin-paclitaxel in patients with non-small-cell lung cancer receiving thoracic radiation.

248 l versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expression o

249 l according to the time interval between non-small-cell lung cancer resection and the initiation of p

250 cacious when started 7 to 18 weeks after non-small-cell lung cancer resection.

251 d as a novel therapeutic target expressed in small cell lung cancer (SCLC) and high-grade neuroendocr

252 ng mouse models of lung cancer, we show that small cell lung cancer (SCLC) and lung adenocarcinoma (A

253 Using small cell lung cancer (SCLC) as a model, we demonstrate

254 Small cell lung cancer (SCLC) is a common, aggressive ma

255 Small cell lung cancer (SCLC) is a devastating disease d

256 Small cell lung cancer (SCLC) is a devastating neuroendo

257 Small cell lung cancer (SCLC) is a difficult to treat su

258 Small cell lung cancer (SCLC) is characterized by preval

259 ich was markedly upregulated in Lu-iPSCs and small cell lung cancer (SCLC) lines and clinical specime

260 ic cell lines and xenografts of melanoma and small cell lung cancer (SCLC) origin.

261 genetically engineered mouse model of human small cell lung cancer (SCLC) to investigate the mechani

262 ludes typical carcinoid, atypical carcinoid, small cell lung cancer (SCLC), and large cell NE cancer.

263 Small cell lung cancer (SCLC), as a proportion, makes up

264 Denny et al. address this question for small cell lung cancer (SCLC), finding that changes in g

265 plification are frequent oncogenic events in small cell lung cancer (SCLC).

266 ranial irradiation has been proposed in both small-cell lung cancer (SCLC) and non-small-cell lung ca

267 Small-cell lung cancer (SCLC) is a highly aggressive sub

268 pite favorable responses to initial therapy, small-cell lung cancer (SCLC) relapse occurs within a ye

269 Purpose Treating small-cell lung cancer (SCLC) remains a therapeutic chal

270 Effective targeted therapies for small-cell lung cancer (SCLC), the most aggressive form

271 In most patients with small-cell lung cancer (SCLC)-a metastatic, aggressive d

272 side for treatment of extensive-disease (ED) small-cell lung cancer (SCLC).

273 platin and etoposide in extensive stage (ES) small-cell lung cancer (SCLC).

274 ients with FGFR1-amplified squamous cell non-small-cell lung cancer (sqNSCLC; arm 1) or other solid t

275 e mutational "hotspots" in nonsmall cell and small cell lung cancers, supporting a possible role of o

276 Patients who recover slowly from non-small-cell lung cancer surgery may still benefit from de

277 st signal was detected in a patient with non-small cell lung cancer (SUVmax, 10.9; T/B ratio, 8.4) an

278 cation of double-positive human NCI-H358 non-small cell lung cancer target tumors over single-positiv

279 LST group undergoing surgery for stage 1 non-small cell lung cancer, those in the SEER-Medicare NLST

280 r shown that knock-out of YAP sensitizes non-small cell lung cancer to EGFR inhibitor Erlotinib.

281 mal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to EGFR inhibitors have been ide

282 The high genomic instability of non-small cell lung cancer tumors leads to the rapid develop

283 Thus, small-cell lung cancer tumours generate their own microe

284 Eleven patients with inoperable non-small cell lung cancer underwent 2-5 thoracic PET/MRI sc

285 Small cell lung cancer was identified as an independent

286 tactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer was reviewed for developmental ri

287 cally proven or radiologically suspected non-small cell lung cancer were prospectively enrolled in th

288 t-related adverse events in 74 patients with small-cell lung cancer were thrombocytopenia (eight [11%

289 platinum-based adjuvant chemotherapy in non-small-cell lung cancer were used as part of the LACE-Bio

290 atients who had squamous or non-squamous non-small-cell lung cancer, were 18 years or older, had meas

291 cly available gene expression dataset of non-small cell lung cancer when combined with the existing p

292 to treat multiple brain metastases from non-small-cell lung cancer when highly active targeted thera

293 f this phenomenon occurs in ALK-positive non-small cell lung cancer, where targeted therapies are use

294 s particularly active in platinum-refractory small-cell lung cancer, which tends not to respond to to

295 in patients with advanced ALK-rearranged non-small-cell lung cancer who had previously progressed fol

296 -naive patients with completely resected non-small-cell lung cancer who received postoperative multia

297 atients with EGFR-mutant or ALK-positive non-small-cell lung cancer with brain metastases now have th

298 ars with ALK-rearranged stage IIIB or IV non-small-cell lung cancer (with at least one measurable les

299 In contrast, a non-small cell lung cancer xenograft expressing a constituti

300 a subcutaneous HER3 overexpressing H441 non-small cell lung cancer xenograft.